-
Mashup Score: 29INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer - 27 day(s) ago
Stay informed with latest cancer breakthroughs, treatments, updates from leading hematology oncology experts. Insights from top cancer conferences and podcasts.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 54Oncology Brothers Event Registration - 28 day(s) ago
Thank you for your interest in attending the Oncology Brothers’ live event, “Advancements in Oncology: Today’s Data for Tomorrow’s Practice,” hosted by Drs. Rahul and Rohit Gosain, coinciding with SABCS 2024. Event Details: Date: Wednesday, December 11, 2024 Time: 7-9 PM (7 PM: Cocktails & Networking; 7:30-9 PM: Panel Discussions) Location: The Moon’s Daughter @ The Thompson Hotel; 115 Lexington Ave, 20th Fl, San Antonio, TX For questions, changes, or other inquiries please contact Kerrie Keegan: Kerrie@SignifyMD.com
Source: docs.google.comCategories: General Medicine News, Partners & KOLsTweet-
Going to be at #SABCS24? Let’s discuss the current SoC & how the data from #SABCS24 is impacting our practice! InPerson: Dec 11, 2024 w/ @DrSGraff @curijoey @hmcarthur @DrGattiMays @drsarahsam @Neil_Iyengar Register https://t.co/l6gxYlEiyq #AdvInOnc24 #bcsm #OncTwitter https://t.co/IPItA5aSL2
-
-
Mashup Score: 40How to Approach and Treat Pancreatic Cancer - 1 month(s) ago
Stay informed with latest cancer breakthroughs, treatments, updates from leading hematology oncology experts. Insights from top cancer conferences and podcasts.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#GISeries: current treatment landscape/algorithm for #PancreaticCancer w/ @EileenMOReilly 🌟PARPi, mFOLFIRINOX, liposomal irinotecan, etc! Full 🗣️ - https://t.co/qoi0Qz1S5f - https://t.co/48cg3gm4Oc - Also on “Oncology Brothers” podcast #OncTwitter #MedTwitter @CancerNetwrk https://t.co/dZudrgYslZ
-
-
Mashup Score: 31Understanding the Impact of Nutrition & Exercise on Cancer Outcomes - 1 month(s) ago
Stay informed with latest cancer breakthroughs, treatments, updates from leading hematology oncology experts. Insights from top cancer conferences and podcasts.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#SupportiveCare: Role of diet & exercise in #cancer w/@Neil_Iyengar! A common question pts ask: “what can I do?” Full Disc: ⭐️ https://t.co/25ENF4cqFP ⭐️ https://t.co/MkA7iOgxeO ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #PallOnc #SuppOnc #bcsm #gusm https://t.co/ARWgWIus47
-
-
Mashup Score: 39Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - 1 month(s) ago
This ESMO Clinical Practice Guideline (CPG) focuses on invasive cutaneous melanoma. The management of uveal melanoma and non-melanoma skin cancers are described in separate ESMO CPGs. Mucosal melanoma is described in the Supplementary Material Section 1 and Supplementary Table S1.
Source: www.annalsofoncology.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† https://t.co/cYLfB07sdE h…
-
-
Mashup Score: 35How to Diagnose, Treat, and Follow Neuroendocrine Tumors (NETs) - 1 month(s) ago
Stay informed with latest cancer breakthroughs, treatments, updates from leading hematology oncology experts. Insights from top cancer conferences and podcasts.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#GISeries: current treatment landscape/algorithm for #NET w/ @PamelaKunzMD 🌟Surgery, Scans, SSA, PRRT, Cabozantinib, etc! Full 🗣️ - https://t.co/obTHRmglcj - https://t.co/ZvLvZDvO3Y - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter @CancerNetwrk #gism https://t.co/pmAm80x6Hu
-
-
Mashup Score: 37Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - 1 month(s) ago
This ESMO Clinical Practice Guideline (CPG) focuses on invasive cutaneous melanoma. The management of uveal melanoma and non-melanoma skin cancers are described in separate ESMO CPGs. Mucosal melanoma is described in the Supplementary Material Section 1 and Supplementary Table S1.
Source: www.annalsofoncology.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† https://t.co/cYLfB07sdE h…
-
-
Mashup Score: 1Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment - 1 month(s) ago
Drug-induced aHUS is rare; however, early diagnosis is vital to reduce morbidity and mortality. With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the …
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
@BijoyTelivala @nihardesai7 @BrownJHM @NicoGagelmann @nickmmark @schowardjd @KirtanPatolia @DrAkhilX @CPSolvers @Geeky_Foodie Saw this during my training and given there was no response to PLEX, we tried Eculizumab and thought that is what helped this patient recover. https://t.co/ysKll9QvAf
-
-
Mashup Score: 31Palliative Care Management in Cancer - 1 month(s) ago
Stay informed with latest cancer breakthroughs, treatments, updates from leading hematology oncology experts. Insights from top cancer conferences and podcasts.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#PalliativeCare: Essential & often misunderstood. w/Drs JanetAbrahm & @IshwariaMD we🗣️symptom management to emotional support! Full Disc: ⭐️ https://t.co/IbpAZpKTsd ⭐️ https://t.co/nQMeoLIn1y ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #MedTwitter #PallOnc #SuppOnc https://t.co/oi3yTGf8yQ
-
-
Mashup Score: 30Atezolizumab/bevacizumab and lenvatinib for hepatocellular... : Hepatology Communications - 2 month(s) ago
-world effectiveness of LEN to atezolizumab/bevacizumab (AZ/BV). Methods: A retrospective analysis was conducted to evaluate the effectiveness and safety of frontline AZ/BV or LEN therapy in patients with advanced HCC across 18 university hospitals in Europe. Results: The study included 412 patients (AZ/BV: n=207; LEN: n=205). Baseline characteristics were comparable between the 2 treatment groups. However, patients treated with AZ/BV had a significantly longer median progression-free survival compared to those receiving LEN. The risk of hepatic decompensation was significantly higher in patients with impaired baseline liver function (albumin-bilirubin [ALBI] grade 2) treated with AZ/BV compared to those with preserved liver function. Patients with alcohol-associated liver disease had poorer baseline liver function compared to other etiologies and exhibited a worse outcome under AZ/BV. Conclusions: In this real-world cohort, survival rates were similar between patients treated with LEN
Source: journals.lww.comCategories: General Medicine News, Partners & KOLsTweet-
RT @ArndtVogel: 🔥off the press - our 🇪🇺RWD study: Atezolizumab/bevacizumab and lenvatinib for HCC @HepCommJournal https://t.co/RGmQUWazG8…
-
#SABCS23 late breaking abstract to @US_FDA approval: Inavolisib based off #INAVO120 we 🗣️ design, findings, and AEs/management w/ @jhaveri_komal Full Discussion: - https://t.co/X3E7Hx6WdH - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #HemeTwitter #SABCS24 https://t.co/7MXh6matkZ